EWA
MACK

Exencial Wealth Advisors’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Exencial Wealth Advisors’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-1,907
Closed -$61K – 174
2016
Q4 		$61K Buy
+1,907
New +$81.3K 0.03% 167

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TA
Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Exencial Wealth Advisors's MACK Position: Q1 2017 in Review

Exencial Wealth Advisors sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q1 2017, closing a stake of 1,907 shares — an estimated $61K sold.

Exencial Wealth Advisors first reported a position in MACK in Q4 2016 and held it in 1 quarter. The position peaked at $61K in Q4 2016. 116 funds tracked by Wall St. Rank hold MACK as of Q1 2017.

  • Exencial Wealth Advisors reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
  • Exencial Wealth Advisors sold 1,907 Merrimack Pharmaceuticals, Inc. shares in Q1 2017, an estimated $61K.
  • Exencial Wealth Advisors first reported a position in Merrimack Pharmaceuticals, Inc. in Q4 2016 and held it in 1 quarter.
  • Exencial Wealth Advisors's Merrimack Pharmaceuticals, Inc. position peaked at $61K in Q4 2016.
  • 116 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q1 2017.

Based on Exencial Wealth Advisors's 13F filing for Q1 2017, filed 26 Apr 2017.